2023 年年度股东大会决议公告 证券代码：301281 证券简称：科源制药 公告编号：2024-041 山东科源制药股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间：2024年4月19日（星期四）15:00 2、现场会议召开地点：山东省济南市历城区经十东路30766号力诺智慧园山 东力诺制药有限公司第二会议室。 3、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为：2024年4月19日 9：15-9：25，9:30—11:30，13:00—15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024年4月19日 9:15—15:00期间的任意时间。 4、召开方式：本次股东大会采取现场投票与网络投票相结合的方式召开。 5、召集人：公司董事会 6、现场会议主持人：公司董事长蒋红升先生 7、本次会议的召集、召开与表决程序符合《中华人民共和国公司法》《上 ...

证券代码：301281 证券简称：科源制药 公告编号：2024-040 山东科源制药股份有限公司 关于使用部分闲置募集资金及自有资金进行现金管理到期 赎回并继续进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于 2023 年 4 月 25 日召开 第三届董事会第五次会议、第三届监事会第五次会议，于 2023 年 5 月 16 日召开 2022 年年度股东大会，审议通过了《关于使用部分闲置募集资金及自有资金进 行现金管理的议案》，同意在不影响公司募集资金投资计划正常进行的前提下， 同意公司在确保不影响募集资金投资项目建设和正常生产经营的情况下，使用不 超过人民 70,000 万元的闲置募集资金和不超过人民币 60,000 万元的自有资金进 行现金管理，有效期自公司 2022 年年度股东大会审议通过之日起 12 个月内，在 前述额度和有效期限内，可循环滚动使用。具体内容详见公司 2023 年 4 月 26 日 披露于巨潮资讯网（www.cninfo.com.cn）的《关于使用部分闲置募集资金及自 ...

Revenue and Profitability - The company's revenue for Q1 2024 was ¥146,276,963.82, representing a 17.75% increase compared to ¥124,226,061.67 in the same period last year[5] - Net profit attributable to shareholders decreased by 32.90% to ¥21,532,537.03 from ¥32,088,662.63 year-on-year[5] - Basic and diluted earnings per share fell by 64.07% to ¥0.1988 from ¥0.5533 in the previous year[5] - Operating profit decreased to CNY 24,428,408.78, down 31.2% from CNY 35,551,888.48 in the same period last year[21] - The company reported a total comprehensive income of CNY 21,523,763.06 for Q1 2024, compared to CNY 32,088,662.63 in Q1 2023[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥1,640,883.14, a decline of 111.59% compared to ¥14,153,258.65 in Q1 2023[11] - Cash inflow from investment activities totaled 3,527,905,218.34, with a net cash flow of 209,416,222.37, contrasting with a negative cash flow of -13,409,829.68 in the prior period[23] - The net increase in cash and cash equivalents was 209,036,937.77, compared to 783,423,545.31 in the previous period, showing a decrease in liquidity[24] - The ending balance of cash and cash equivalents was 568,547,454.88, down from 932,397,769.05, indicating a reduction in available cash[24] Assets and Liabilities - Total assets increased by 2.31% to ¥1,503,869,639.53 from ¥1,469,967,974.01 at the end of the previous year[5] - Total liabilities rose to CNY 152,038,788.17, compared to CNY 138,927,726.47 in the previous year[19] - The company's total equity increased to CNY 1,351,830,851.36, up from CNY 1,331,040,247.54 year-over-year[19] - The company reported a total current asset of ¥830,437,539.40, down from ¥878,788,621.84, a decrease of 5.49%[17] Operational Performance - The company's operating costs rose by 50.02% to ¥85,598,444.16, primarily due to an increase in the quantity of products sold[11] - The company experienced a 45.21% increase in selling expenses, amounting to ¥20,930,375.42, attributed to higher promotional costs[11] - The total cash outflow from operating activities was 89,961,054.86, which increased from 86,085,059.99, indicating higher operational costs[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,298[13] - The largest shareholder, Linuo Investment Holdings, holds 34.39% of shares, totaling 37,240,000 shares, with 23,340,000 shares pledged[13] - The total number of preferred shareholders at the end of the reporting period is not applicable[15] - There are no significant changes in the top 10 shareholders due to margin trading activities[14] Investment Activities - Investment activities generated a net cash flow of ¥209,416,222.37, a substantial increase of 1,661.66% compared to -¥13,409,829.68 in Q1 2023[11] - The company invested 3,231,843,016.67 in cash payments for investments, a significant amount reflecting aggressive investment strategies[23] - The cash received from the recovery of investments was 3,526,111,048.66, indicating strong investment recovery efforts[23] Research and Development - Research and development expenses for Q1 2024 were CNY 8,784,714.80, compared to CNY 8,110,172.85 in Q1 2023, reflecting a growth of 8.3%[20] Other Financial Metrics - The weighted average return on equity decreased to 1.60% from 5.99% year-on-year, reflecting a decline of 4.39%[5] - Deferred income tax assets decreased to CNY 2,673,457.45 from CNY 2,924,149.53 year-over-year[18] - The company has a goodwill of ¥1,820,994.04, which was not present in the previous period[17] - Inventory decreased to ¥99,354,540.88 from ¥108,054,744.66, a decline of 8.06%[17] - Non-current assets include long-term equity investments of ¥183,080,078.52, unchanged from the previous period[17] - Accounts receivable rose to ¥76,303,134.71 from ¥43,398,750.30, marking an increase of 75.73%[17]

中信建投证券股份有限公司 关于山东科源制药股份有限公司 2023 年度跟踪报告 | 保荐机构名称：中信建投证券股份有限公司 | 被保荐公司简称：科源制药 | | --- | --- | | 保荐代表人姓名：杨慧泽 | 联系电话：010-56051417 | | 保荐代表人姓名：王辉 | 联系电话：010-86451030 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、监督公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、募 | 是 | | 集资金管理制度、内控制度、内部审计制度、 | | | 关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件 ...

证券代码：301281 证券简称：科源制药 公告编号：2024-037 山东科源制药股份有限公司 关于首次公开发行前部分限售股解禁并上市流通的提示性公告 一、首次公开发行股份概况和上市后股本变化情况 （一）首次公开发行股份概况 经中国证券监督管理委员会《关于同意山东科源制药股份有限公司首次公开发行 股票注册的批复》（证监许可〔2023〕362 号）同意注册，并经深圳证券交易所《关于 山东科源制药股份有限公司人民币普通股股票在创业板上市的通知》（深证上〔2023〕 260 号）同意，山东科源制药股份有限公司首次公开发行人民币普通股（A 股）股票 19,350,000 股，并于 2023 年 4 月 4 日在深圳证券交易所创业板上市。 首次公开发行股票完成后公司总股本为 77,350,000 股，其中有流通限制或限售安 排的股票数量为 58,999,171 股，占发行后总股本的比例为 76.28%；其中无流通限制 及限售安排的股票数量为 18,350,829 股，占发行后总股本的比例为 23.72%。 （二）上市后股本变动情况 2023 年 5 月 26 日，公司实施 2022 年年度权益分派方案，以 77,35 ...

中信建投证券股份有限公司 关于山东科源制药股份有限公司 首次公开发行前部分限售股解禁并上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"）作为山 东科源制药股份有限公司（以下简称"公司"或"科源制药"）首次公开发行股票并 在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号—— 保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等有关法律法规和规范性文件的要求，对科源制药首次公开发行前部 分限售股解禁并上市流通事项进行了核查，并出具核查意见如下： 一、首次公开发行股份概况和上市后股本变化情况 （一）首次公开发行股份概况 经中国证券监督管理委员会《关于同意山东科源制药股份有限公司首次公开 发行股票注册的批复》（证监许可〔2023〕362 号）同意注册，并经深圳证券交 易所《关于山东科源制药股份有限公司人民币普通股股票在创业板上市的通知》 （深证上〔2023〕260 号）同意，山东科源制药股份有限公司首次公开发行人民 币普通股（A 股）股票 19,350, ...

中信建投证券股份有限公司 关于山东科源制药股份有限公司 2023 年度定期现场检查报告 | 保荐机构名称：中信建投证券股份有 被保荐公司简称：科源制药 | | --- | | 限公司 | | 保荐代表人姓名：杨慧泽 联系电话：010-56051417 | | 保荐代表人姓名：王辉 联系电话：010-86451030 | | 现场检查人员姓名：王辉、苏山 | | 现场检查对应期间：2023 年度 | | 现场检查时间：2024 年 3 月 26 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段：查阅公司相关制度性文件；查阅公司历次董事会、监事会、股东 | | 大会等会议资料；查阅公司相关信息披露文件；与公司相关负责人进行沟通 | | 1.公司章程和公司治理制度是否完备、合规 √ | | 2.公司章程和三会规则是否得到有效执行 √ | | 3.三会会议记录是否完整，时间、地点、出席人员及会议内 √ | | 容等要件是否齐备，会议资料是否保存完整 | | √ 4.三会会议决议是否由出席会议的相关人员签名确认 | | 公司董监高是否按照有关法律法规和本所相关业务 ...

Financial Performance - The company's operating revenue for 2023 was CNY 447,583,620.32, representing a 1.07% increase compared to CNY 442,865,098.55 in 2022[25]. - The net profit attributable to shareholders decreased by 15.60% to CNY 77,039,439.15 from CNY 91,278,406.78 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 65,450,732.83, down 23.10% from CNY 85,112,132.04 in 2022[25]. - The cash flow from operating activities decreased significantly by 68.04% to CNY 37,030,989.82 from CNY 115,858,735.33 in 2022[25]. - Basic and diluted earnings per share fell by 32.14% to CNY 0.76 from CNY 1.12 in 2022[25]. - Total assets increased by 125.53% to CNY 1,469,967,974.01 at the end of 2023, compared to CNY 651,789,219.99 at the end of 2022[25]. - The net assets attributable to shareholders rose by 156.10% to CNY 1,331,040,247.54 from CNY 519,728,016.81 in 2022[25]. - The company achieved a revenue of 447.58 million yuan in 2023, representing a year-on-year growth of 1.07%[74]. - The net profit attributable to shareholders was 77.04 million yuan, a decrease of 15.60% compared to the previous year[75]. - Total assets increased to 1,469.97 million yuan, up 125.53% from the beginning of the period, primarily due to funds raised from the IPO[74]. Dividend Distribution - The company plans to distribute a cash dividend of 3 RMB per 10 shares to all shareholders, based on a total of 108,290,000 shares[4]. - The board of directors has approved a profit distribution plan, with no bonus shares to be issued[4]. - The total cash dividend distributed amounts to ¥32,487,000, representing 100% of the total profit distribution[196]. - The distributable profit as of December 31, 2023, is ¥265,529,817.49[196]. - The company prioritizes cash dividends when conditions allow, with a minimum cash distribution of 20% for companies in a growth phase with significant capital expenditures[191]. Market Position and Strategy - The company is focused on expanding its market presence and enhancing its product offerings through new product development and technology[4]. - The global pharmaceutical market is projected to reach USD 1.90 trillion by 2027, with a compound annual growth rate of 3%-6%[36]. - The Chinese pharmaceutical market is expected to reach CNY 31,945 billion by 2030, with a compound annual growth rate of 6.30% from 2019 to 2030[37]. - The company has established a strong market position in the raw material drug sector, benefiting from national centralized procurement policies[70]. - The company is actively pursuing an integrated development strategy of "raw materials + formulations" through acquisitions, such as the purchase of Lino Pharmaceutical[69]. Research and Development - The company focuses on R&D and innovation, increasing its R&D investment to enhance its technological capabilities, which are closely aligned with its core products and future development plans[41]. - The company is actively engaged in R&D for new products, with ongoing projects aimed at expanding its product portfolio[53]. - Research and development expenses increased by 30% to 150 million CNY, focusing on innovative drug formulations and delivery systems[172]. - The company plans to focus on the research and development of chemical raw materials in areas such as diabetes, anesthesia, cardiovascular, and mental health, while also expanding into digestive, hemostatic, analgesic, and anti-inflammatory fields[130]. Risk Management - The company emphasizes the importance of risk management and outlines potential risks and countermeasures in its future development outlook[4]. - The company faces risks related to changes in national policies, market supply and demand fluctuations, and rising upstream raw material prices, which could impact profit margins[133]. - The company is at risk of not passing consistency evaluations and winning national procurement bids for its main formulation products[136]. - The company will closely monitor exchange rate fluctuations and improve foreign exchange management to mitigate risks[137]. Governance and Management - The company has a complete and independent operational system, ensuring no reliance on its controlling shareholders[148]. - The company has conducted two shareholder meetings during the reporting period, with all resolutions passed legally and effectively[142]. - The company’s governance structure is sound, with a clear separation of powers among the board, supervisory board, and management[145]. - The company reported a leadership change with Jiang Hongsheng appointed as Chairman and General Manager in October 2023, following the retirement of previous executives[159]. - The company is in the process of appointing new directors and executives, including the election of Wu Bin as a director and Wang Jianwei as the new General Manager[159]. Financial Management - The company has established and effectively implemented internal control systems in compliance with regulatory requirements[198]. - There were no significant internal control deficiencies reported during the period[199]. - The company has received government subsidies related to income amounting to ¥3,992,164.91, which accounted for 5.01% of total profit[100]. - The company has not engaged in any derivative investments during the reporting period[117]. Employee Management - The total number of employees at the end of the reporting period is 624, with 480 in the parent company and 144 in major subsidiaries[186]. - The professional composition includes 325 production personnel, 54 sales personnel, 116 technical personnel, 15 financial personnel, 28 administrative personnel, and 86 others[186]. - Training programs are implemented to enhance employee skills in safety, environmental awareness, and quality, contributing to the company's high-quality development[189].

证券代码：301281 证券简称：科源制药 公告编号：2024-033 山东科源制药股份有限公司 关于使用部分闲置募集资金及自有资金进行现金管理的 山东科源制药股份有限公司（以下简称"公司"或"科源制药"）于 2024 年 3 月 28 日召开第三届董事会第十四次会议、第三届监事会第十二次会议， 审议通过了《关于使用部分闲置募集资金及自有资金进行现金管理的议案》， 同意公司在确保不影响募集资金投资项目建设和正常生产经营的情况下，使用 不超过人民 40,000 万元的闲置募集资金和不超过人民币 30,000 万元的自有资 金进行现金管理，有效期自公司 2023 年年度股东大会审议通过之日起 12 个月 内，在前述额度和有效期限内，可循环滚动使用。具体情况如下: 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意山东科源制药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2023〕362 号）同意注册，并经深圳证 券交易所同意，公司首次向社会公众公开发行人民币普通股（A 股）1,935.00 万股，每股发行价 44.18 元,募集资金总额为人民币 854,883,000.00 元，扣除 发行费用 8 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司（以下简称"公司"）于2024年3月28日召开第 三届董事会第十四次会议，审议通过了《关于提请股东大会授权董事会办理以简 易程序向特定对象发行股票相关事宜的议案》，本议案尚需提交公司2023年年度 股东大会审议通过。 现将具体内容公告如下： 一、本次授权事项概述 为进一步推动公司业务的发展，公司拟提请股东大会依照《上市公司证券发 行注册管理办法》《深圳证券交易所上市公司证券发行上市审核规则》《深圳证 券交易所上市公司证券发行与承销业务实施细则》及《公司章程》等有关规定， 授权董事会在不影响公司主营业务及保证公司财务安全的前提下，择机办理向特 定对象发行融资总额不超过人民币3亿元且不超过最近一年末净资产20%的股票 事宜，授权期限为本次授权相关议案经公司2023年年度股东大会审议通过之日起 至2024年度股东大会召开之日止。具体情况如下： 证券代码：301281 证券简称：科源制药 公告编号：2024-030 山东科源制药股份有限公司 关于提请股东大会授权董事会办理以简易程序 向特定对象发行 ...